title: Influence of consecutive-day blood sampling on polymerase chain reaction-adjusted parasitological cure rates in an antimalarial-drug trial conducted in Tanzania.
abstract: We assessed the influence that consecutive-day blood sampling, compared with single-day blood sampling, had on polymerase chain reaction (PCR)-adjusted parasitological cure after stepwise genotyping of merozoite surface proteins 2 (msp2) and 1 (msp1) in 106 children in Tanzania who had uncomplicated falciparum malaria treated with either sulfadoxine-pyrimethamine or artemether-lumefantrine; 78 of these children developed recurrent parasitemia during the 42-day follow-up period. Initial msp2 genotyping identified 27 and 33 recrudescences by use of single- and consecutive-day sampling, respectively; in subsequent msp1 genotyping, 17 and 21 of these episodes, respectively, were still classified as recrudescences; these results indicate a similar sensitivity of the standard single-day PCR protocol--that is, 82% (27/33) and 81% (17/21), in both genotyping steps. Interpretation of PCR-adjusted results will significantly depend on methodology.
authors.affiliation: Infectious Diseases Unit, Department of Medicine, Karolinska University Hospital, Stockholm 17176, Sweden. andreas.martensson@ki.se
authors.forename: Andreas
authors.initials: A
authors.lastname: Martensson
authors.forename: Billy
authors.initials: B
authors.lastname: Ngasala
authors.forename: Johan
authors.initials: J
authors.lastname: Ursing
authors.forename: M
authors.initials: M
authors.lastname: Isabel Veiga
authors.forename: Lisa
authors.initials: L
authors.lastname: Wiklund
authors.forename: Christopher
authors.initials: C
authors.lastname: Membi
authors.forename: Scott M
authors.initials: SM
authors.lastname: Montgomery
authors.forename: Zul
authors.initials: Z
authors.lastname: Premji
authors.forename: Anna
authors.initials: A
authors.lastname: Farnert
authors.forename: Anders
authors.initials: A
authors.lastname: Bjorkman
mesh_terms: D000818:Animals; D000953:Antigens, Protozoan / Q000235:genetics; D000962:Antimalarials / Q000627:therapeutic use; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000627:therapeutic use*; D016054:DNA, Protozoan / Q000097:blood* / Q000235:genetics; D004338:Drug Combinations; D004983:Ethanolamines / Q000627:therapeutic use*; D005449:Fluorenes / Q000627:therapeutic use*; D005838:Genotype; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000469:parasitology*; D020066:Merozoite Surface Protein 1 / Q000235:genetics; D010963:Plasmodium falciparum / Q000145:classification / Q000235:genetics / Q000302:isolation & purification*; D016133:Polymerase Chain Reaction; D015800:Protozoan Proteins / Q000235:genetics; D011739:Pyrimethamine / Q000627:therapeutic use*; D012008:Recurrence; D013413:Sulfadoxine / Q000627:therapeutic use*; D013636:Tanzania
chemical_list: D000953:Antigens, Protozoan; D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D016054:DNA, Protozoan; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; D020066:Merozoite Surface Protein 1; D015800:Protozoan Proteins; C065974:merozoite surface protein 2, Plasmodium; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine